Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia in the Daily Clinical Practice. (TARGET)
Study Details
Study Description
Brief Summary
This is a multi-centre, observational, ambispective study, which will retrospectively and prospectively collect clinical and socio-demographic data from medical records of patients with HTN and dyslipidemia initiated with SPC of amlodipine/atorvastatin/perindopril in real clinical settings.
A total of 80 general practitioners and outpatient cardiologists will participate in this non-interventional study 400 patients should be included in the study.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Treatment with the studied drug:
-
Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg
-
Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 5 mg
-
Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 10 mg This is non-interventional study that is observational by its nature. Therefore there will be no any assignments of subjects to a particular therapeutic strategies defined by this protocol. Decision to treat a patient with SPC of amlodipine/ atorvastatin/ perindopril should be at the descretion of a treating investigator and made in accordance to local standards and protocols.
Study Design
Outcome Measures
Primary Outcome Measures
- To describe antihypertensive effectiveness of a triple single-pill combination of amlodipine, atorvastatin and perindopril at 12 weeks in patients with arterial hypertension (HTN) and dyslipidemia in the daily clinical practice. [12 weeks]
Mean change from baseline in SBP (systolic blood pressure) and DBP (diastolic blood pressure) assessed at week 12 of the observational period.
- To describe hypolipidaemic effectiveness of a triple single-pill combination of amlodipine, atorvastatin and perindopril at 12 weeks in patients with arterial hypertension (HTN) and dyslipidemia in the daily clinical practice. [12 weeks]
Mean change from baseline in LDL-C ( low density lipoprotein cholesterol) assessed at week 12 of the observational period
Secondary Outcome Measures
- To determine the proportion of patients who reached systolic (SBP) and diastolic blood pressure (DBP) target goals at weeks 4 and 12 of the observation period respectively. [12 weeks]
- To determine the proportion of patients who reached LDL-C target goals at week 12 of the observation period. [12 weeks]
- To evaluate the quality of life of patients at visit 1 (V1) and visit 2 (V2) as compared to visit 0 (V0) respectively [12 weeks]
Mean change from V0 in scores of the SF-36 questionnaire assessed at V1 and V2;
- To evaluate the adherence to treatment with the fixed dose combination of amlodipine/atorvastatin/perindopril in patients included into the study at V1 and V2 as compared to V0 [12 weeks]
Proportion of patients with high, moderate and low adherence to the treatment with SPC (single pill combination) of amlodipine/atorvastatin/perindopril at V1 as compared to V0 via medication adherence scale; Proportion of patients with high, moderate and low adherence to the treatment with SPC of amlodipine/atorvastatin/perindopril at V2 as compared to V0 via medication adherence scale;
- To evaluate predictors of reaching BP target goals in the study population [12 weeks]
Proportion of patients achieving target BP levels depending on baseline SBP and DBP;
- To evaluate predictors of reaching LDL-C target goals in the study population [12 weeks]
Proportion of patients achieving target levels LDL C depending on baseline LDL-C level.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Obtained signed informed consent from the patient
-
Patients of 18 years and older and younger than 80 years.
-
Start of the treatment with SPC of amlodipine/atorvastatin/perindopril within 1 month from the Index date in accordance with the indication in Russian SmPC.
-
Presence of the parameters of interest* in the medical records dated with the nearest to the start of SPC amlodipine/atorvastatin/perindopril treatment date.
-
Parameters of interest include measured at rest office BP and LDL-C.
Exclusion Criteria:
-
Subjects who are unwilling or unable to provide a signed informed consent form;
-
Any contraindication to the treatment with the SPC of amlodipine/atorvastatin/perindopril according to its' approved instruction for medical use in the Russian Federation;
-
Concomitant use of any other ACE inhibitors, CCBs, ARBs and statins.
-
Supposed low treatment adherence to the assigned SPC and the risk for poor collaboration between the patient and the investigator during the study;
-
Any severe, decompensated or unstable somatic diseases or states that according to investigator discretion are life-threatening or worsen the prognosis for the patient: myocardial infarction in the past 3 months, unstable angina, current decompensation of diabetes mellitus, autoimmune or oncological diseases, severe cardiac arrhythmia, gastrointestinal disorders affecting absorbtion, severe hepatic diseases, pancreatic diseases, severe allergic reactions, connective tissue diseases etc;
-
Secondary arterial hypertension;
-
Alcohol or any drug abuse;
-
Surgical intervention on heart or coronary vessels (i.e., heart valve(s) replacement, stent implantation or CABG), or any non-cardiological serious surgical intervention that are planned within next 3 months and may require withdrawal or changes in current therapy;
-
Glomerular filtration rate less than 60 ml/min/1,72m2;
-
Participating in any other clinical trial currently or during 30 days period before informed consent was signed.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Servier Russia
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IC4-05153-070-RUS